Rogier Rooswinkel PhD
General Partner
Optimizing a unique (NK)-1 neurokinin antagonist pipeline.
NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.
Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients, is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy, and there are no approved treatments for it. IPF has been designated an orphan disease in both Europe and the USA. Preparations for the start of the Phase 2 trial to evaluate orvepitant as a treatment for disabling chronic cough associated with IPF are currently underway.
Human Health
UK
Stevenage Bioscience Catalyst
Incubator Building
Stevenage SG1 2FX
Near London
Industry
Biotech
Status
Current
Location
UK
I would like to extend my sincere gratitude to you, Geert-Jan and the entire Forbion team for your exceptional commitment to finance and nurture the two Women’s Health portfolio companies KaNDy and Rathlin Therapeutics. It is so rewarding to see the regulatory approval of “Lynkuet” a non-hormonal treatment for symptoms of the menopause, by the FDA in the US, ( EMA in Europe)* and the MHRA in the UK. Bringing innovative medicines to patients is our ultimate purpose.Mary Kerr
CEO of NeRRe Therapeutics
£20m
Series B2 financing
Forbion team
Geert-Jan Mulder MD
Managing Partner